A

LS has proven stubbornly resistant to medicinal breakthroughs, with just one new drug securing U.S. approval in the last 22 years. Cytokinetics (CYTK) hopes to change that with the readout of a large clinical trial within the next two weeks.

Success will require beating long odds. Here are seven things you need to know about Cytokinetics and its experimental ALS drug tirasemtiv before the clinical trial results are announced.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • David Salinas. I am not sure where your comment comes from. The basic DP costs about $200/mo. I don’t sell it and don’t control the price. You can buy it from Simplesa or buy the substances separately online. They are all on Amazon.

  • ALS patients respond to the DP which suppresses muscle symptoms and can be cured by a combination of antibiotics b/c it is caused by Borrelia and co-infections. So many dead, so much money wasted.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.